Biomedical Engineering Reference
In-Depth Information
Gatignon H, Hanssens DM (1987) Modeling marketing interactions with application to salesforce
effectiveness. J Mark Res 24(2):247-257
Gönül FF, Carter FJ (2010) Impact of e-detailing on the number of new prescriptions. Health Care
Manag Sci 13(2):101-111
Grabowski H (2002) Patents, innovations and access to new pharmaceuticals, working paper
(July). Duke University, Durham
Gschwandtner G (2011) How many salespeople will be left by 2020. Selling Power, 30 July.
Available at
http://www.sellingpower.com/magazine/article.php?i=1363&ia=9293
Hagerty MR, Carman JM, Russell GJ (1988) Estimating elasticities with PIMS data: methodologi-
cal issues and substantive implications. J Mark Res 25(1):1-9
Hanssens D (ed) (2009) Empirical generalizations about marketing impact. Marketing Science
Institute, Relevant Knowledge Series, Cambridge
Henningsen S, Heuke R, Clement M (2011) Determinants of advertising effectiveness: the devel-
opment of an international advertising elasticity database and a meta-analysis. Bus Res Offi cial
Open Access J 4(2):193-239
Hensley S (2007) Pharma box offi ce: sales force shifts. Wall Street J Online, 6 Jun 2013
Heutschi R, Legner C, Scheisser A, Barak V,
Ö
sterle H (2003) Potential benefi ts and challenges of
e-detailing in Europe. Int J Med Mark 3(4):263-273
Iizuka T, Jin GZ (2007) Direct to consumer advertising and prescription choice. J Ind Econ
55(4):771-786
Iskowitz M, Arnold M (2011) Pharma report 2011: cliff notes. Med Mark Media (May):40-46.
Available at mmm-online.com
Joseph K, Mantrala MK (2009) A model of the role of free drug samples in physicians' prescrip-
tion decisions. Mark Lett 20:15-29
Kolsarici C, Vakratsas D (2010) Category-versus brand-level advertising messages in a highly
regulated environment. J Mark Res 47(6):1078-1089
Kremer STM, Bijmolt THA, Leefl ang PSH, Wieringa JE (2008) Generalizations on the effective-
ness of pharmaceutical promotional expenditures. Int J Res Mark 25(4):234-246
LaMotta L (2010) How big pharma will survive the patent cliff, April 21. Available at
http://www.
LaMotta L (2010) The next big opportunity for big pharma is BRIC, March 11. Available at
http://
Leefl ang PSH, Wittink DR, Wedel M, Naert PA (2000) Building models for marketing decisions.
Kluwer Academic, Norwell, MA
Liang BA, Mackey T (2011) Reforming direct-to-consumer advertising. Nat Biotechnol
29(5):397-400
Lodish LM, Curtis E, Ness M, Kerry Simpson M (1988) Sales force sizing and deployment using
a decision calculus model at Syntex Laboratories. Interfaces 18(1):5-20
Manchanda P, Chintagunta PK (2004) Responsiveness of physician prescription behavior to sales-
force effort: an individual level analysis. Mark Lett 15(2-3):129-145
Manchanda P, Honka E (2005) The effects and role of direct-to-physician marketing in the phar-
maceutical industry: an integrative review. Yale J Health Policy Law Econ 5(2):785-822
Manchanda P, Rossi PE, Chintagunta PK (2004) Response modeling with nonrandom marketing-
mix variables. J Mark Res 61:467-478
Mantrala MK, Albers S (2010) Impact of the Internet on B2B sales force size and structure,
(December), forthcoming in Handbook of B2B Marketing, (eds: Gary Lilien and Raj
Grewal, ISBM, Penn State University), Elgar Publishing
Mantrala MK, Sinha P, Zoltners A (1994) Structuring a multiproduct sales quota-bonus plan for a
heterogeneous sales force: a practical model-based approach. Mark Sci 13(2 Spring):121-144
Nair HS, Manchanda P, Bhatia T (2010) Asymmetric social interactions in physician prescription
behavior: the role of opinion leaders. J Mark Res 47(5):883-895
Search WWH ::
Custom Search